Does Pennsylvania Medicaid cover Zepbound?

Quick answer · Weight Loss

Pennsylvania Medicaid does not cover it for weight loss on Medicaid.

The card and program names below are mapped to Pennsylvania Medicaid in our records. Coverage depends on the reason for treatment and the requirements in the policy.

Policy last verified June 4, 2026. Policy effective January 1, 2026. Source: mab2025112403.pdf. How we verify this data.

Card and program names on file in Pennsylvania

Select a name to read the Pennsylvania Medicaid policy for Zepbound. These are names we recognize, including older names and spelling variants; this is not a list of plans currently accepting members.

Don't see your card name? Check your card or call the pharmacy-benefit number on your card. If you also have Medicare, confirm which plan handles this prescription.

Zepbound for Weight Loss

Medicaid

Not covered

Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The policy states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'

Policy note: Pennsylvania MA explicitly ended coverage of all GLP-1 receptor agonists for overweight/obesity effective January 1, 2026. Class-wide exclusion applies to Zepbound for weight_loss indication.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf

Zepbound for Osa

Medicaid

Covered with requirements

What you need to qualify

  • BMI of 35 or higher
  • Prior trial of 3 other GLP-1 medications (Ozempic, Wegovy, and Mounjaro)
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy

Qualification pathways

You can qualify through any one of these.

Initial approval — Zepbound for moderate-to-severe OSA (non-preferred)

All of:

  • Recent BMI >= 35 kg/m2
  • Diagnosis of moderate to severe OSA confirmed within the last 2 years per most recent consensus treatment guidelines (e.g., AASM ICSD) OR baseline AHI >= 15 events/hour
  • At least one clinical OSA symptom: excessive daytime sleepiness (e.g., ESS >= 10) OR reduced sleep-related quality of life (snoring, nocturnal choking, insomnia, partner sleep disruption, morning headaches, nocturia, etc.)
  • Recent 6-month trial of lifestyle changes and behavioral modifications OR medical reason why immediate treatment is necessary
  • Age-appropriate per FDA labeling, compendia, or peer-reviewed literature
  • No contraindication to the prescribed drug
  • History of therapeutic failure of, OR contraindication to, OR intolerance to the maximum FDA-approved doses of Ozempic (semaglutide), Wegovy (semaglutide), AND Mounjaro (tirzepatide)

Plus any one of:

  • Utilization of PAP with documented adherence (>= 4 hours/night on 70% of nights in a consecutive 30-day period)
  • PAP intolerance despite troubleshooting (mask issues, humidity, claustrophobia) AND: utilization of or intolerance to an oral appliance for OSA

Documentation to bring

  • Recent BMI documentation (>= 35 kg/m2)
  • Documentation of moderate-to-severe OSA diagnosis within last 2 years: per AASM/consensus guidelines OR AHI >= 15 events/hour on sleep study
  • Documentation of at least one OSA clinical symptom: ESS score >= 10 (excessive daytime sleepiness) OR sleep-related quality of life impairment (snoring, nocturnal choking, insomnia, partner disruption, morning headaches, nocturia)
  • PAP adherence documentation: >= 4 hours/night on 70% of nights in a consecutive 30-day period — OR documentation of PAP intolerance with troubleshooting attempts AND utilization of or intolerance to an oral appliance
  • Documentation of 6-month prior trial of lifestyle changes and behavioral modifications OR medical reason for immediate treatment
  • Documentation of therapeutic failure of Ozempic (semaglutide) at max FDA-approved dose, AND Wegovy (semaglutide) at max FDA-approved dose, AND Mounjaro (tirzepatide) at max FDA-approved dose — OR contraindication/intolerance to each (with troubleshooting documentation over >= 1 month if intolerance-based)
  • Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
  • Documentation of no contraindication to Zepbound
  • If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Renewal (OSA): (1) If on GLP-1 <6 months: documentation of lifestyle changes and behavioral modifications; (2) If on GLP-1 >=6 months AND titration complete AND >=3 consecutive months at max tolerated dose: must show 5% total body weight loss and documentation of dietary changes; (3) If on GLP-1 >=6 months but titration not complete or <3 consecutive months at max tolerated dose: may approve up to 3-month trial extension at max tolerated dose with documentation of dietary changes; (4) PAP adherence or PAP intolerance with oral appliance trial maintained; (5) If on GLP-1 >=1 year: must document improvement in OSA symptoms (e.g., decrease in AHI from baseline, improvement in daytime sleepiness); (6) Step-therapy: therapeutic failure/contraindication/intolerance to max doses of Ozempic, Wegovy, AND Mounjaro. BMI and AHI baseline not re-confirmed at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Mild OSA excluded (moderate-to-severe only, AHI >= 15)
  • Overweight/obesity treatment indication excluded
  • Saxenda (liraglutide) not covered for any indication

Policy note: Zepbound is non-preferred for OSA. Requires step-through therapeutic failure/contraindication/intolerance to maximum FDA-approved doses of ALL THREE of: Ozempic, Wegovy, AND Mounjaro before Zepbound. OSA diagnosis must be confirmed within last 2 years. PAP adherence is defined as >= 4 hours/night on 70% of nights in a consecutive 30-day period. PAP intolerance pathway requires documentation of troubleshooting strategies (mask issues, humidity, claustrophobia) and then either use of or intolerance to an oral appliance. Renewal at >=6 months requires 5% total body weight loss (if titration complete and >=3 months at max tolerated dose) with dietary change documentation; if not yet at max dose, up to 3-month extension may be approved. At >=1 year, must document OSA symptom improvement (AHI reduction or daytime sleepiness improvement). Approval up to 6 months per cycle unless reviewer specifies otherwise. Prescriptions limited to 1-month supply per fill.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf

Full Pennsylvania Medicaid coverage page for Zepbound

Other medications under Pennsylvania Medicaid

All insurance plans · All medications

This page summarizes written Medicaid policies on file. It is not a guarantee of coverage or medical advice. Confirm your current benefits and prior-authorization requirements with your plan.